US 20210260037A1

(19) United States

(12) Patent Application Publication

BOCCI et al.

(10) Pub. No.: US 2021/0260037 A1

(43) Pub. Date: Aug. 26, 2021

(54) **MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA**

(71) Applicants: **UNIVERSITA' DI PISA**, Pisa (IT); **UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA**, Modena (IT)

(72) Inventors: **Guido BOCCI**, Pisa (IT); **Teresa DI DESIDERO**, Pisa (IT); **Daniela GIULIANI**, Modena (IT); **Salvatore GUARINI**, Modena (IT); **Paola ORLANDI**, Pisa (IT); **Alessandra OTTANI**, Modena (IT); **Carla Maria Francesca PARDINI**, Pisa (IT); **Francesca VAGLINI**, Pisa (IT)

(21) Appl. No.: **17/253,883**

(22) PCT Filed: **Jun. 14, 2019**

(86) PCT No.: **PCT/IB2019/054992**

§ 371 (c)(1),
(2) Date: **Dec. 18, 2020**

(30) **Foreign Application Priority Data**

Jun. 18, 2018 (IT) 102018000006399

Publication Classification

(51) **Int. Cl.**

A61K 31/4164	(2006.01)
A61K 45/06	(2006.01)
A61K 31/437	(2006.01)
A61P 35/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/4164*** (2013.01); ***A61P 35/00*** (2018.01); ***A61K 31/437*** (2013.01); ***A61K 45/06*** (2013.01)

(57) **ABSTRACT**

A method of therapeutic treatment of a tumor pathology including melanoma, tumors of the gastrointestinal tract, and/or thyroid carcinoma by administering to a subject in need thereof melanocortin receptor-4 (MC4R) antagonists is provided. The melanocortin receptor-4 antagonists are suitable in a targeted anti-tumor treatment, and particularly in an adjuvant therapy or in a therapy affecting onset and/or progression of tumor metastasis. A pharmaceutical composition including a melanocortin receptor-4 (MC4R) antagonist in a pharmaceutically acceptable vehicle, and in combination with optional adjuvants, stabilizers and/or preservatives, is also provided.